Colorectal cancer remains one of the most commonly diagnosed malignancies worldwide, and its rising incidence in younger adults has baffled oncologists for more than a decade. While established risk factors such as age, genetics, physical inactivity, and diets heavy in red and processed meat are well documented, researchers have increasingly turned their attention to ultra-processed foods (UPFs) — industrial formulations manufactured from substances derived from foods, combined with cosmetic additives including emulsifiers, colorants, sweeteners and stabilizers. The NOVA classification system, which sorts foods according to their degree of industrial processing, has allowed epidemiologists to track consumption patterns, and the data reveal a dramatic global shift. Systematic reviews show that in some countries UPFs now account for more than half of daily caloric intake, and consumption trends continue to climb in regions as diverse as Europe, Asia and the Americas. This nutritional transition, the authors note, has coincided with rising rates of obesity, metabolic syndrome and colorectal cancer, prompting scientific scrutiny of the additives that give UPFs their signature properties.

Emulsifiers occupy a central place in that scrutiny. These molecules possess both water-loving and fat-loving regions, allowing them to bind oil and water into stable mixtures that would otherwise separate. Lecithins, mono- and diglycerides of fatty acids, polysorbate 80, carboxymethylcellulose, carrageenan and related compounds are added to thousands of products, from mayonnaise and margarine to plant-based milks and processed meats. Regulatory agencies in the United States and the European Union have long deemed these substances safe at approved concentrations, and industry reviews have generally supported that assessment. Yet the new review synthesizes a growing body of evidence suggesting that the question of emulsifier safety cannot be answered by traditional toxicology alone, because these additives interact with the trillions of microbes that inhabit the human gut — an ecosystem whose disruption, known as dysbiosis, is increasingly implicated in chronic disease.

The mechanistic case against emulsifiers begins with the mucus layer, the gel-like barrier that separates gut bacteria from the epithelial cells lining the intestine. In a healthy gut, this layer maintains a critical physical separation; most commensal bacteria live in the outer mucus, while the inner, densely packed layer keeps microbial products away from host tissue. Experimental work summarized in the review indicates that emulsifiers can alter the structure and transport properties of intestinal mucus, effectively thinning this defensive front. When the barrier is compromised, bacterial components such as lipopolysaccharide and flagellin gain access to the epithelial surface, triggering pattern-recognition receptors and activating inflammatory signaling cascades — most notably the NF-κB pathway, a master switch of intestinal inflammation whose chronic activation is a recognized feature of colitis-associated carcinogenesis.

The microbiome itself is transformed in the process. Landmark animal studies published in Nature in 2015 demonstrated that mice consuming water supplemented with common emulsifiers such as polysorbate 80 and carboxymethylcellulose developed profound shifts in microbial composition, including an expansion of bacteria capable of degrading mucus and an encroachment of microbes closer to the epithelium. These microbial changes drove low-grade intestinal inflammation and, over time, metabolic syndrome. Later research extended the findings, showing that emulsifier-exposed mice exhibited increased colitis severity, and that in genetically susceptible models, emulsifier consumption promoted the development of intestinal tumors. Crucially, the effects were not uniform: the impact of a given emulsifier depended on the composition of each animal’s resident microbiota, helping to explain why some individuals may be more vulnerable than others.

Human evidence, while more limited, is mounting. An ex vivo study using fecal samples from healthy donors found that several dietary emulsifiers directly altered human microbiota composition and gene expression in ways that potentiated intestinal inflammation, with marked person-to-person variability. More definitive was a randomized controlled-feeding trial published in Gastroenterology, in which healthy volunteers consumed carboxymethylcellulose at levels consistent with a high-UPF diet. The intervention shifted the participants’ microbiota toward an inflammatory profile, reduced microbial diversity, and encroached bacteria on the epithelium; metabolomic analysis revealed corresponding changes in short-chain fatty acids and other microbial products. Additional randomized work with carrageenan — a seaweed-derived emulsifier — suggested that even in people with quiescent ulcerative colitis, exposure could influence inflammatory markers and gastrointestinal symptoms, raising concern for patients whose intestinal barriers are already compromised.

Perhaps the most provocative findings come from large prospective human cohorts. The French NutriNet-Santé study, which follows more than 100,000 adults, published results in PLoS Medicine in 2024 linking higher intake of specific food additive emulsifiers to elevated overall cancer risk, with suggestive associations for several emulsifier classes and breast cancer in particular. While observational data of this kind cannot establish causation — people who eat more UPFs differ from others in many dietary and lifestyle respects — the findings align closely with the mechanistic literature and have intensified calls for regulatory reevaluation. The review also highlights disturbing animal data on developmental programming: offspring of mice fed emulsifiers during pregnancy and lactation showed metabolic and neuropsychological alterations, and emulsifier exposure accelerated the development of type 1 diabetes in genetically prone mice, suggesting that consequences may extend far beyond the gut of the individual consumer.

So how might emulsifier-induced dysbiosis translate specifically into colorectal cancer? The review lays out a plausible sequence. Barrier erosion allows bacterial penetration; the resulting chronic inflammation generates reactive oxygen and nitrogen species that damage epithelial DNA and drive compensatory cell proliferation. Dysbiosis simultaneously favors tumor-promoting species — the best-characterized being Fusobacterium nucleatum, an anaerobe enriched in colorectal tumors that has been shown to promote chemoresistance by modulating autophagy in cancer cells. At the same time, a depleted, inflammation-altered microbiota produces less butyrate and other short-chain fatty acids, the protective metabolites that normally nourish colonocytes, reinforce tight junctions and restrain immune overreaction. The net effect is an environment in which damaged cells survive, proliferate and evade immune surveillance — the essential ingredients of carcinogenesis. Experimental work dating back decades, including studies showing that germ-free animals can be protected from certain tumor-inducing chemicals, laid the conceptual foundation: the microbiota is not a bystander in colon cancer but an active participant whose diet-driven manipulation matters.

The authors are careful to frame their conclusions as a call for research rather than a definitive verdict. Observational studies confounded by overall dietary patterns, strain differences in animal models, the vast heterogeneity among emulsifier types, and person-to-person microbiome variability all complicate the picture. Some additive-safety reviews have concluded that current exposures pose no demonstrable risk. Nonetheless, the convergence of animal experiments, human feeding trials and prospective cohort data has, in the authors’ view, reached a threshold that warrants action on two fronts: the identification of demonstrably safe food additives, and the development of targeted interventions — including microbiome-modulating strategies, fermented foods, dietary fiber restoration and whole-food-based approaches — aimed at restoring gut homeostasis in vulnerable populations.

For consumers, the practical implications are pragmatic rather than alarmist. Reading ingredient labels for polysorbate 80, carboxymethylcellulose and carrageenan; substituting minimally processed foods for UPF staples where feasible; and emphasizing fiber-rich and fermented foods that support microbial diversity are all measures consistent with existing dietary guidance. For regulators, the review adds colorectal cancer to the growing list of outcomes — metabolic syndrome, inflammatory bowel disease, autoimmune conditions — that must be weighed in reevaluating food additive approvals. As the authors conclude, understanding the relationship among diet, emulsifiers and gut microbiota can guide dietary recommendations and regulatory policies to reduce colorectal cancer risk. Given that ultra-processed foods now supply such a large share of global calories, even a modest effect on cancer risk would translate into a substantial public health burden — one that may, at least in part, be preventable through the reformulation of the foods billions of people eat every day.